Real-World Comparison of Gene-Matched vs. Non-Gene-Matched Therapy Outcomes Using Integrated Genomic and Clinical Data.

ABSTRACT: Previous studies have demonstrated that 10%-25% of patients receive gene-matched therapy (GMT) after comprehensive genomic profiling (CGP). However, its real-world clinical effects remain unclear. This study assessed the feasibility of integrating the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) repository that documented genomic and clinical data and the quality indicator (QI) dataset that included cancer-specific data and administered treatment as a model case of real-world data study of cancer genomic medicine in Japan. We successfully integrated these two datasets and included 1162 patients diagnosed with solid tumors at the National Cancer Center Hospital between 2019 and 2021 who underwent CGP testing. Of these, 432 (37.2%) had druggable mutations, 96 (8.3%) received

SUBMITTER: Ishii T 

PROVIDER: S-EPMC12485814 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature